Loading…
Loading…
EQUITY / NASDAQ · XNCM
HCW Biologics Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.6409 USD · -2.3274%
Observed: Oct 2, 2026, 11:39 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 1.68 USD · Volume 66,536
21 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Revenue | 121,730 USD | — | — |
| Operating profit | -3,166,289 USD | -3,464,077 USD | — |
| Net income | -5,219,231 USD | -1,927,730 USD | — |
| Cash and cash equivalents | 741,324 USD | — | — |
| Total liabilities | 19,340,704 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 741,324 USD | — | — | 1,952,464 USD | 1,952,464 USD | 1,096,909 USD | — | — |
| Gross profitIncome statement | -93,887 USD | 6,438,043 USD | — | — | 10,846 USD | 3,121 USD | 5,445 USD | 1,310 USD |
| Net incomeIncome statement | -5,219,231 USD | -1,746,751 USD | 3,472,480 USD | — | -7,959,709 USD | -4,554,336 USD | -8,678,941 USD | -1,927,730 USD |
| Operating profitIncome statement | -3,166,289 USD | 69,420 USD | — | — | -13,162,510 USD | -3,292,126 USD | -8,700,688 USD | -3,464,077 USD |
| RevenueIncome statement | 121,730 USD | 6,700,000 USD | — | — | — | — | — | — |
| Total assetsBalance sheet | 26,768,318 USD | — | — | 24,520,013 USD | 24,520,013 USD | 25,445,540 USD | — | — |
| Total equityBalance sheet | 7,427,614 USD | — | 5,762,434 USD | 2,764,769 USD | 2,764,769 USD | -2,107,197 USD | — | -51,972 USD |
| Total liabilitiesBalance sheet | 19,340,704 USD | — | — | 21,755,244 USD | 21,755,244 USD | 27,552,737 USD | — | — |
| Financing cash flowCash flow statement | — | 4,330,224 USD | — | — | 10,669,509 USD | — | 6,458,437 USD | — |
| Operating cash flowCash flow statement | — | -5,541,364 USD | — | — | -13,391,617 USD | — | -10,036,100 USD | — |
| Capital expendituresCash flow statement | — | — | — | — | 0 USD | — | 0 USD | — |
| Investing cash flowCash flow statement | — | — | — | — | 0 USD | — | 0 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 03/31/2026 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.